Mark Pegram
Academic Appointments
- Professor - Med Center Line, Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Stanford Women�s Cancer Center 900 Blake Wilbur Stanford, CA 94305 Tel Work (650) 498-6004 Fax (650) 490-7237
- Academic Offices
Personal Information Tel (650) 723-5801Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Breast Cancer
- Oncology
Professional Education
| Internship: | Univ Of Texas Southwestern TX (1987) |
| Residency: | Univ Of Texas Southwestern TX (1987) |
| Board Certification: | Oncology, American Board of Internal Medicine (1993) |
| Fellowship: | UCLA - School of Medicine CA (1993) |
| Board Certification: | General Internal Medicine, American Board of Internal Medicine (1989) |
| Medical Education: | University of North Carolina NC (1986) |
Scientific Focus
Clinical Trials
- Recruiting Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
- Recruiting An Extension Study of Trastusumab Emtansine in Patients Previously Treated With Trastusumab Emtansine
- Not Recruiting A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
- Not Recruiting PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
- Recruiting The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Publications
- The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat. 2013; (3): 783-94
- Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene. 2013; (19): 2463-74
- PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat. 2012; (3): 683-92
- Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012; (1): 215-23
- Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Res Treat. 2012; (3): 919-26
- Tumor biology trumps anatomy in breast cancer brain metastases. Oncology (Williston Park). 2012; (7): 666, 668, 670
Help
Trial Administration